FDA Adverse Event Injury Summary report: N

GORE EXCLUDER AAA ENDOPROSTHESIS

MDR report key: 1001911 · Received February 21, 2008

Report

Report Number
2953161-2008-00025
Event Type
Injury
Date Received
February 21, 2008
Date of Event
January 28, 2008
Report Date
February 21, 2008
Manufacturer
W. L. GORE & ASSOCIATES, INC.
Product Code
MIH
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NJ, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

A REVIEW OF THE MANUFACTURING PAPERWORK HAS BEEN CONDUCTED. THE REVIEW OF THE MANUFACTURING PAPERWORK VERIFIED THAT THIS LOT MET ALL PRE-RELEASE SPECIFICATIONS. ANEURYSM GROWTH IN THE ABSENCE OF ENDOLEAKS HAS BEEN DEFINED AS ENDOTENSION IN THE LITERATURE. ONE HYPOTHESIS FOR THE SOURCE OF ENDOTENSION IS THE TRANSMURAL MOVEMENT OF SERIOUS FLUID ACROSS THE MATERIAL USED TO FABRICATE DEVICES USED TO TREAT THE AORTIC ABDOMINAL ANEURYSM. EVIDENCE SUPPORTING THIS HYPOTHESIS HAS BEEN GATHERED DURING SURGICAL CONVERSIONS, TRANSLUMBAR PUNCTURES OF THE AORTIC ABDOMINAL ANEURYSM, AND LAPAROSCOPIC EXPLORATION OF AORTIC ABDOMINAL ANEURYSM SAC CONTENTS. DUE TO THESE OBSERVATIONS GORE ELECTED TO PROVIDE A DESIGN ENHANCEMENT TO THE ORIGINAL GORE EXCLUDER BIFURCATED ENDOPROSTHESIS. THE DEVICE USED IN THIS PARTICULAR CASE WAS THE ORIGINAL GORE EXCLUDER BIFURCATED ENDOPROSTHESIS. PLEASE NOTE ATTACHED LIST OF ADDITIONAL DEVICES IMPLANTED IN THIS PATIENT: PCL161007/022243607, PCC121000/032051407.

Description of Event or Problem · 1

IN 2004, THIS PATIENT UNDERWENT ENDOVASCULAR REPAIR OF AN ABDOMINAL AORTIC ANEURYSM USING GORE EXCLUDER BIFURCATED ENDOPROSTHESIS. ANEURYSM ENLARGEMENT WITH ABSENCE OF AN ENDOLEAK WAS NOTED IN 2008. A REINTERVENTION TOOK PLACE ONE MONTH LATER, TO RELINE THE DEVICES USING ADDITIONAL ENDOPROSTHESIS. THE PROCEDURE WENT WELL.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 GORE EXCLUDER AAA ENDOPROSTHESIS ENDOVASCULAR GRAFT SYSTEM MIH W. L. GORE & ASSOCIATES, INC. WLG325 021260305

Patients

Seq Age Sex Outcome Treatment
1 YR Required Intervention